UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...

The STEER study showed significant motor function improvement in children with SMA using intrathecal onasemnogene abeparvovec. The primary efficacy endpoint was met with a 2.39-point improvement ...

Indeed, although the trial missed its secondary endpoints, intrathecal (IT) Zolgensma (onasemnogene abeparvovec or OAV101 IT) elicited a 2.39-point improvement on the Hammersmith Functional Motor ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

Once we lose a motor neuron, it's not able to be regenerated in any way with current treatment and science. This is an irreversible loss of something very important that happens in this disease.

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

Conti will package its brake components with a patented dual-rotor, radial-flux motor, supplied by DeepDrive, to drive the wheels. The technology will be road-ready soon, the partners say ...